WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
World Court orders Israel to halt Gaza famine; Hamas says ceasefire neededGovernment's transport plan costly to society and climate, 88 academics warnFallen 'Crypto King' Sam BankmanSome Auckland train services cancelledNZ could breach European free trade deal if it doesn't meet Paris Agreement obligationsWorld Court orders Israel to halt Gaza famine; Hamas says ceasefire neededFour things to watch out for as Americans votePrincess of Wales Kate having chemotherapy after cancer discoveryMinistry for the Environment asks for voluntary redundanciesWatch: PM Christopher Luxon announces building products shake
2.4319s , 6605.3515625 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Starry Scope news portal